uniQure Receives NASDAQ Deficiency Letter Related To Board Composition

Lexington, MA and Amsterdam, the Netherlands, September 16, 2016 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that it has received a letter from NASDAQ dated September 12, 2016, stating that the Company does not currently comply with the requirement under NASDAQ Listing Rule 5605 that at least a majority of the Company's Board consist of independent directors. Currently, four of the eight members of the Company's Board meet NASDAQ's independence standards; this is a result of the retirements from the Board of independent directors Ferdinand Verdonck and Joseph Fezko effective as of the Company's 2016 annual general meeting of shareholders. Under the NASDAQ rules, the Company has until the earlier of its next annual shareholders' meeting or June 15, 2017 to regain compliance with the majority independent board requirement (or until December 12, 2016, if the Company holds its next annual general meeting of shareholders prior to such date). The Company intends to achieve compliance with this requirement prior to the expiration of this cure period.

About uniQure

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with liver/metabolic, central nervous system and cardiovascular diseases. www.uniQure.com